US5171251003
US5171251003
Larimar Therapeutics, Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | -- | -- | -- |
| Cost of Revenue | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| 172.497.000 | 90.890.000 | 89.8% | |
| Operating Income | -172.497.000 | -90.890.000 | 89.8% |
| Pretax Income | -165.673.000 | -80.604.000 | 105.5% |
| Net Income Common Stockholders | -165.673.000 | -80.604.000 | 105.5% |
| -- | -- | -- | |
| -- | -- | -- |